Cure Alzheimer's Fund Cure Alzheimer's Fund

Fine Mapping of Prioritized GWAS Results

2008

In this application we propose to utilize next-generation sequencing combined with high-efficiency genomic sequence capture to systematically fine-map the 14q31 region which, based on the currently available data, very likely contains an important AD susceptibility locus(i). Newly identified variants will be followed up in more than 5,500 DNAs from both family-based and case-control backgrounds.

Foundational Genetic Risk Factors Lars Bertram

Funding to Date

$127,880

Focus

Foundational, Genetic Risk Factors

Researchers

Lars Bertram, M.D.

Related Content:


Plasma Proteins, Sex and Alzheimer’s Disease: Proteome-Wide Analyses of the UK Biobank and Framingham Heart Study P. Murali Doraiswamy 2024-12-16 Relationship Between Alzheimer’s Disease Risk Score and Outcomes of Mild Repetitive Neurotrauma Thomas McAllister Michael McCrea 2024-12-16 Alzheimer’s Disease PET Imaging of Nonfibrillar Amyloid Beta Aggregates Using Azapeptide (AZP) Tracer Sam Gandy Brigitte Guérin Shai Rahimipour William Lubell 2024-12-16 Investigating the Serial Pathologies Related to Plasma Biomarkers in NLFTaum/h Mice: A New Mouse Model Featuring Neurofibrillary Tangles as a Result of Rising Amyloid Beta without Microtubule-Associated Protein Tau (MAPT) Mutations Frances Edwards John Hardy 2024-12-16 Integrating Single-Cell Genomics for Pathways to Protection and Resilience Against Alzheimer’s Disease Winston Hide 2024-10-31 Midlife Autoantibody Profiles and the Risk of Late-Onset Alzheimer’s Disease in Women Yu Chen 2024-10-31 Mapping the X Chromosome Multi-Ome in Alzheimer’s and Parkinson’s Disease Michael Belloy 2024-09-17 Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform) Ali Ezzati 2024-09-16